Crossref
Targeting the JAK-STAT pathway: Successful use of abrocitinib in refractory prurigo nodularis
Indian Journal of Skin Allergy · 20.03.2026 · 5 · 105-106
DOI: 10.25259/ijsa_83_2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Skin Allergy, online erschienen am 20.03.2026. Verfasst von Abhishek De und 3 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
De, A., Singh, A., Chakraborty, D., & Ahmed, S. K. S. (2026). Targeting the JAK-STAT pathway: Successful use of abrocitinib in refractory prurigo nodularis. Indian Journal of Skin Allergy, 5, 105-106. https://doi.org/10.25259/ijsa_83_2025
Vancouver
De A, Singh A, Chakraborty D, Ahmed SKS. Targeting the JAK-STAT pathway: Successful use of abrocitinib in refractory prurigo nodularis. Indian Journal of Skin Allergy. 2026;5:105-106. doi:10.25259/ijsa_83_2025
BibTeX
@article{De2026,
author = {De, Abhishek and Singh, Apeksha and Chakraborty, Disha and Ahmed, S. K. Shahriar},
title = {Targeting the JAK-STAT pathway: Successful use of abrocitinib in refractory prurigo nodularis},
journal = {Indian Journal of Skin Allergy},
year = {2026},
volume = {5},
pages = {105--106},
doi = {10.25259/ijsa_83_2025}
}
EUVIMED